Cargando…

Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit

Background and Purpose: The European Association of Urology guidelines recommend restaging transurethral resection of bladder tumours (reTURB) 2–6 weeks after primary TURB. However, in clinical practice some patients undergo a second TURB procedure after Bacillus Calmette-Guérin immunotherapy (BCG)i...

Descripción completa

Detalles Bibliográficos
Autores principales: Krajewski, Wojciech, Moschini, Marco, Nowak, Łukasz, Poletajew, Sławomir, Tukiendorf, Andrzej, Afferi, Luca, Teoh, Jeremy, Muilwijk, Tim, Joniau, Steven, Tafuri, Alessandro, Antonelli, Alessandro, Gozzo, Alessandra, Mari, Andrea, Di Trapani, Ettore, Hendricksen, Kees, Alvarez-Maestro, Mario, Serrano, Andrea Rodriguez, Simone, Giuseppe, Zamboni, Stefania, Simeone, Claudio, Marconi, Maria Cristina, Mastroianni, Riccardo, Ploussard, Guillaume, Rajwa, Paweł, Laukhtina, Ekaterina, Zdrojowy-Wełna, Aleksandra, Kołodziej, Anna, Paradysz, Andrzej, Tully, Karl, Krajewska, Joanna, Piszczek, Radosław, Xylinas, Evanguelos, Zdrojowy, Romuald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602446/
https://www.ncbi.nlm.nih.gov/pubmed/33076249
http://dx.doi.org/10.3390/jcm9103306
_version_ 1783603680707084288
author Krajewski, Wojciech
Moschini, Marco
Nowak, Łukasz
Poletajew, Sławomir
Tukiendorf, Andrzej
Afferi, Luca
Teoh, Jeremy
Muilwijk, Tim
Joniau, Steven
Tafuri, Alessandro
Antonelli, Alessandro
Gozzo, Alessandra
Mari, Andrea
Di Trapani, Ettore
Hendricksen, Kees
Alvarez-Maestro, Mario
Serrano, Andrea Rodriguez
Simone, Giuseppe
Zamboni, Stefania
Simeone, Claudio
Marconi, Maria Cristina
Mastroianni, Riccardo
Ploussard, Guillaume
Rajwa, Paweł
Laukhtina, Ekaterina
Zdrojowy-Wełna, Aleksandra
Kołodziej, Anna
Paradysz, Andrzej
Tully, Karl
Krajewska, Joanna
Piszczek, Radosław
Xylinas, Evanguelos
Zdrojowy, Romuald
author_facet Krajewski, Wojciech
Moschini, Marco
Nowak, Łukasz
Poletajew, Sławomir
Tukiendorf, Andrzej
Afferi, Luca
Teoh, Jeremy
Muilwijk, Tim
Joniau, Steven
Tafuri, Alessandro
Antonelli, Alessandro
Gozzo, Alessandra
Mari, Andrea
Di Trapani, Ettore
Hendricksen, Kees
Alvarez-Maestro, Mario
Serrano, Andrea Rodriguez
Simone, Giuseppe
Zamboni, Stefania
Simeone, Claudio
Marconi, Maria Cristina
Mastroianni, Riccardo
Ploussard, Guillaume
Rajwa, Paweł
Laukhtina, Ekaterina
Zdrojowy-Wełna, Aleksandra
Kołodziej, Anna
Paradysz, Andrzej
Tully, Karl
Krajewska, Joanna
Piszczek, Radosław
Xylinas, Evanguelos
Zdrojowy, Romuald
author_sort Krajewski, Wojciech
collection PubMed
description Background and Purpose: The European Association of Urology guidelines recommend restaging transurethral resection of bladder tumours (reTURB) 2–6 weeks after primary TURB. However, in clinical practice some patients undergo a second TURB procedure after Bacillus Calmette-Guérin immunotherapy (BCG)induction. To date, there are no studies comparing post-BCG reTURB with the classic pre-BCG approach. The aim of this study was to assess whether the performance of reTURB after BCG induction in T1HG bladder cancer is related to potential oncological benefits. Materials and Methods: Data from 645 patients with primary T1HG bladder cancer treated between 2001 and 2019 in 12 tertiary care centres were retrospectively reviewed. The study included patients who underwent reTURB before BCG induction (Pre-BCG group: 397 patients; 61.6%) and those who had reTURB performed after BCG induction (Post-BCG group: 248 patients, 38.4%). The decision to perform reTURB before or after BCG induction was according to the surgeon’s discretion, as well as a consideration of local proceedings and protocols. Due to variation in patients’ characteristics, both propensity-score-matched analysis (PSM) and inverse-probability weighting (IPW) were implemented. Results: The five-year recurrence-free survival (RFS) was 64.7% and 69.1% for the Pre- and Post-BCG groups, respectively, and progression-free survival (PFS) was 82.7% and 83.3% for the Pre- and Post-BCG groups, respectively (both: p > 0.05). Similarly, neither RFS nor PFS differed significantly for a five-year period or in the whole time of observation after the PSM and IPW matching methods were used. Conclusions: Our results suggest that there might be no difference in recurrence-free survival and progression-free survival rates, regardless of whether patients have reTURB performed before or after BCG induction.
format Online
Article
Text
id pubmed-7602446
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76024462020-11-01 Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit Krajewski, Wojciech Moschini, Marco Nowak, Łukasz Poletajew, Sławomir Tukiendorf, Andrzej Afferi, Luca Teoh, Jeremy Muilwijk, Tim Joniau, Steven Tafuri, Alessandro Antonelli, Alessandro Gozzo, Alessandra Mari, Andrea Di Trapani, Ettore Hendricksen, Kees Alvarez-Maestro, Mario Serrano, Andrea Rodriguez Simone, Giuseppe Zamboni, Stefania Simeone, Claudio Marconi, Maria Cristina Mastroianni, Riccardo Ploussard, Guillaume Rajwa, Paweł Laukhtina, Ekaterina Zdrojowy-Wełna, Aleksandra Kołodziej, Anna Paradysz, Andrzej Tully, Karl Krajewska, Joanna Piszczek, Radosław Xylinas, Evanguelos Zdrojowy, Romuald J Clin Med Article Background and Purpose: The European Association of Urology guidelines recommend restaging transurethral resection of bladder tumours (reTURB) 2–6 weeks after primary TURB. However, in clinical practice some patients undergo a second TURB procedure after Bacillus Calmette-Guérin immunotherapy (BCG)induction. To date, there are no studies comparing post-BCG reTURB with the classic pre-BCG approach. The aim of this study was to assess whether the performance of reTURB after BCG induction in T1HG bladder cancer is related to potential oncological benefits. Materials and Methods: Data from 645 patients with primary T1HG bladder cancer treated between 2001 and 2019 in 12 tertiary care centres were retrospectively reviewed. The study included patients who underwent reTURB before BCG induction (Pre-BCG group: 397 patients; 61.6%) and those who had reTURB performed after BCG induction (Post-BCG group: 248 patients, 38.4%). The decision to perform reTURB before or after BCG induction was according to the surgeon’s discretion, as well as a consideration of local proceedings and protocols. Due to variation in patients’ characteristics, both propensity-score-matched analysis (PSM) and inverse-probability weighting (IPW) were implemented. Results: The five-year recurrence-free survival (RFS) was 64.7% and 69.1% for the Pre- and Post-BCG groups, respectively, and progression-free survival (PFS) was 82.7% and 83.3% for the Pre- and Post-BCG groups, respectively (both: p > 0.05). Similarly, neither RFS nor PFS differed significantly for a five-year period or in the whole time of observation after the PSM and IPW matching methods were used. Conclusions: Our results suggest that there might be no difference in recurrence-free survival and progression-free survival rates, regardless of whether patients have reTURB performed before or after BCG induction. MDPI 2020-10-15 /pmc/articles/PMC7602446/ /pubmed/33076249 http://dx.doi.org/10.3390/jcm9103306 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Krajewski, Wojciech
Moschini, Marco
Nowak, Łukasz
Poletajew, Sławomir
Tukiendorf, Andrzej
Afferi, Luca
Teoh, Jeremy
Muilwijk, Tim
Joniau, Steven
Tafuri, Alessandro
Antonelli, Alessandro
Gozzo, Alessandra
Mari, Andrea
Di Trapani, Ettore
Hendricksen, Kees
Alvarez-Maestro, Mario
Serrano, Andrea Rodriguez
Simone, Giuseppe
Zamboni, Stefania
Simeone, Claudio
Marconi, Maria Cristina
Mastroianni, Riccardo
Ploussard, Guillaume
Rajwa, Paweł
Laukhtina, Ekaterina
Zdrojowy-Wełna, Aleksandra
Kołodziej, Anna
Paradysz, Andrzej
Tully, Karl
Krajewska, Joanna
Piszczek, Radosław
Xylinas, Evanguelos
Zdrojowy, Romuald
Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit
title Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit
title_full Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit
title_fullStr Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit
title_full_unstemmed Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit
title_short Restaging Transurethral Resection of Bladder Tumours after BCG Immunotherapy Induction in Patients with T1 Non-Muscle-Invasive Bladder Cancer Might not Be Associated with Oncologic Benefit
title_sort restaging transurethral resection of bladder tumours after bcg immunotherapy induction in patients with t1 non-muscle-invasive bladder cancer might not be associated with oncologic benefit
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602446/
https://www.ncbi.nlm.nih.gov/pubmed/33076249
http://dx.doi.org/10.3390/jcm9103306
work_keys_str_mv AT krajewskiwojciech restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT moschinimarco restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT nowakłukasz restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT poletajewsławomir restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT tukiendorfandrzej restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT afferiluca restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT teohjeremy restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT muilwijktim restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT joniausteven restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT tafurialessandro restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT antonellialessandro restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT gozzoalessandra restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT mariandrea restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT ditrapaniettore restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT hendricksenkees restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT alvarezmaestromario restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT serranoandrearodriguez restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT simonegiuseppe restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT zambonistefania restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT simeoneclaudio restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT marconimariacristina restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT mastroianniriccardo restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT ploussardguillaume restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT rajwapaweł restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT laukhtinaekaterina restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT zdrojowywełnaaleksandra restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT kołodziejanna restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT paradyszandrzej restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT tullykarl restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT krajewskajoanna restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT piszczekradosław restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT xylinasevanguelos restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit
AT zdrojowyromuald restagingtransurethralresectionofbladdertumoursafterbcgimmunotherapyinductioninpatientswitht1nonmuscleinvasivebladdercancermightnotbeassociatedwithoncologicbenefit